Eftansomatropin alfa

SHANGHAI and SUZHOU, China, Nov. 24, 2025 /PRNewswire/ -- Phrontline Biopharma ("Phrontline"), a next-generation antibody–drug conjugate (ADC) company, today announced the closing of a $60 million Pre-A+ financing round. The round was led by Lapam Investment, with participation from Samsung Venture Investment Corporation (SVIC), Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures, and Sino Biopharmaceutical Limited. Existing shareholders — Decheng Capital, Medfine Health Fund, and C&D Emerging Investment — also participated and increased their investment in the company. This financing reflects strong investor confidence in Phrontline's differentiated bispecific and dual-payload ADC platforms, its strategically designed pipeline, and its rapidly expanding global development capabilities. Proceeds will support advancement of the company's clinical-stage and preclinical ADC programs, expansion of global clinical operations, and strengthening of key strategic partnerships. Building a Leading Bispecific and Dual-Payload ADC Platform Founded in 2022, Phrontline is among the first biotechnology companies globally to focus on bispecific antibody ADCs (BsAb-ADCs) and dual-payload ADCs. The company has built an end-to-end ADC platform spanning antibody discovery, linker–payload engineering, site-specific conjugation, and functional characterization — resulting in a proprietary, highly differentiated technology engine. Leveraging this platform, Phrontline has designed multiple dual-target combinations and complementary payload strategies tailored to specific tumor indications and has advanced nearly ten innovative ADC programs. Among them, TJ101, a bispecific ADC targeting EGFR and B7-H3, is currently enrolling patients in parallel first-in-human clinical trials in China and the United States. Preclinical data demonstrate superior efficacy and safety relative to peer programs, positioning TJ101 as one of the leading next-generation EGFR/B7-H3 bispecific ADC candidates worldwide. Strategic Collaborations Accelerating Global Expansion. On October 20, 2025, Phrontline announced a global strategic collaboration with Samsung Bioepis. Under the terms of the agreement, the companies will jointly develop two next-generation bispecific, dual-payload ADC candidates with differentiated mechanisms of action, leveraging Phrontline's proprietary BsAb and dual-payload ADC platforms. On October 31, 2025, Phrontline entered into an exclusive license agreement with Sino Biopharmaceutical Limited for TJ101 in Mainland China and the Hong Kong SAR. Sino Biopharmaceutical will make an upfront payment of an undisclosed amount, along with potential development and commercial milestone payments and sales-based royalties. This collaboration represents a key inflection point for Phrontline's lead asset as it transitions into accelerated global clinical development. Advancing Next-Generation ADCs Through Science and Conviction "From the beginning, our strategy has been guided by biology and translational science. We believe that dual-target synergy and complementary payload mechanisms can unlock new therapeutic options for patients whose tumors are resistant to current therapies," said Tony Chen, Ph.D., Founder and Chief Executive Officer of Phrontline Biopharma. "Our preclinical and emerging clinical data are beginning to validate this vision." "We are deeply grateful to both our new and existing investors for their continued confidence in Phrontline," Dr. Chen added. "This financing marks an important milestone for the company and will allow us to accelerate our clinical programs and global expansion as we work to deliver truly innovative ADC medicines to patients around the world." Investor Perspective "Phrontline is a highly execution-focused and resilient team," said Ji Wang, Investment Lead at Lapam Investment. "By leveraging its proprietary bispecific antibody and dual-payload ADC platforms, the company has built a differentiated pipeline aimed at major unmet medical needs. Its preclinical data show compelling efficacy and safety and demonstrate the strong scalability of its platform. "We look forward to supporting Phrontline as its programs advance through clinical development and as the company continues to drive innovation in next-generation ADC therapeutics," Wang added. About Phrontline Biopharma Phrontline Biopharma is a biotechnology company dedicated to the research and development of next-generation ADCs. Founded in 2022 by a team of seasoned industry veterans with deep and complementary experience in ADC drug discovery and development, Phrontline has built a globally competitive platform for bispecific and dual-payload ADCs. The company has established a robust pipeline of innovative candidates spanning preclinical to early clinical stages and is committed to advancing a new paradigm in precision oncology through scientific innovation and to bringing transformative therapies to patients worldwide. SOURCE Phrontline Biopharma 21% more press release views with Request a Demo

SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. "This is a critical milestone for Phrontline as we advance our mission to deliver innovative ADC therapies that can meaningfully impact patients' lives," said Zhaoyuan "Tony" Chen, Chief Executive Officer of Phrontline Biopharma. "The initiation of this study not only represents the progress of our lead candidate, TJ101, but also demonstrates the strength of our platform and the dedication of our team in advancing breakthrough science into the clinic. Running this trial in both China and the United States reflects our commitment to a truly global clinical development strategy and ensures early alignment with international regulatory standards." The Phase 1 study of TJ101 will evaluate its safety, tolerability, pharmacokinetics, and preliminary antitumor activity across multiple solid tumor types. The study design includes dose escalation followed by expansion cohorts to further assess TJ101's potential in a broad patient population. "This first patient dosing is a major step forward in validating our ADC platform," said Martín Sebastian Olivo, MD, Chief Medical Officer of Phrontline Therapeutics. "Our team has worked tirelessly to design a program that explores the full clinical potential of TJ101 while also laying the groundwork for our broader pipeline of differentiated ADCs. Beyond TJ101, we are advancing a portfolio of next-generation bispecific d ual payload ADCs, which aim to overcome resistance mechanisms seen with current therapies and broaden the scope of patients who may benefit." Phrontline's pipeline includes multiple early-stage ADC assets targeting high-value tumor antigens. The company's dual payload platform leverages a modular design with optimized linker stability and distinct mechanisms of action, enabling improved tumor penetration and a stronger bystander effect. "By combining scientific innovation with a clear clinical strategy, we are building a robust ADC pipeline that we believe can transform the standard of care in oncology," added Dr. Chen. About Phrontline Biopharma Phrontline Biopharma is a biotechnology company headquartered in Suzhou, China, focused on developing next-generation Antibody-Drug Conjugates (ADCs) for the treatment of solid tumors. Leveraging proprietary linker-drug technology and a differentiated dual payload approach, Phrontline aims to deliver more effective and durable treatment options for patients with high unmet medical needs. SOURCE Phrontline Biopharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED